Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 7;36(4):917–925. doi: 10.1007/s00467-020-04751-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Swimmer plot grouped according to the outcome. The outcome after the 5-year follow-up period determines the group assignment. In patients 1, 3, 4, 5, 7, 11, 15, 16, 17, and 18, CFH-Ab titers dropped and are negative at 5-year follow-up. In patients 2, 6, 9, 10, 12, 13, 14, and 19, CFH-Ab titers are still detectable at 5-year follow-up but in the low titer range (> 100 and < 600 AU/ml). X-axis: years of observation. Beginning of the bars refers to onset of disease, which was quasi identical to the timepoint of HUS diagnosis (maximum of 2-week difference). Y-axis: group assignment and patient ID. Complete remission: normalization of LDH, haptoglobin, hemoglobin, and platelets in combination with normal kidney function. Partial remission: normalization of LDH, haptoglobin, hemoglobin, and platelets but presence of chronic kidney disease and/or proteinuria [13]. AU arbitrary units, CFH-Ab complement factor H antibodies, CKD stage 5 chronic kidney disease, Ecu eculizumab, HUS hemolytic uremic syndrome, IS any kind of immunosuppressive therapy except eculizumab, PT plasma therapy (any kind)